Intra-Cellular Therapies Inc (NASDAQ: ITCI) has reported a loss for its third fiscal quarter (ending September 30) of $-0.25 versus a loss $-0.25 for the same period a year ago — flat performance. For the latest four quarters through September 30, E.P.S. were $-0.87 compared to $-1.61 a year ago — a decline of -46%.
Recent Price Action
On 10/30/24, Intra-Cellular Therapies Inc (NASDAQ: ITCI) stock enjoyed a major increase of 11.4%, closing at $85.47. Moreover, exceptionally high trading volume at 498% of normal accompanied the advance. Relative to the market the stock has been strong over the last nine months and has risen 10.9% during the last week.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to be in line with the cost of capital, ITCI is expected to continue to be Value Creation neutral.
Intra-Cellular Therapies has a current Value Trend Rating of F (Lowest Rating). This rating combines inconsistent signals from two proprietary PTR measures of a stock’s attractiveness. Intra-Cellular Therapies has a neutral Power Rating of 48 but a very low Appreciation Score of 10, with the Lowest Value Trend Rating the result.
Rating Review
In light of this new information and very positive price change we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment